Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.
## Materials

| Category                  | Availability | Notes                          |
|---------------------------|--------------|-------------------------------|
| Antibodies                | Yes (indicate where provided: section/paragraph) | n/a                           |
|                          |              | For commercial reagents, provide supplier name, catalogue number and RRID, if available. | No antibodies |
| Cell materials            | Yes (indicate where provided: section/paragraph) | n/a                           |
| Cell lines:               |              | Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID | Not Cell lines |
| Primary cultures:         |              | Provide species, strain, sex of origin, genetic modification status. | Not Primary cultures |
| Experimental animals      | Yes (indicate where provided: section/paragraph) | n/a                           |
| Laboratory animals:       |              | Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID | Not Experimental animals |
| Animal observed in or captured from the field: | Provide species, sex and age where possible | Not Experimental animals |
| Model organisms:          |              | Provide Accession number in repository (where relevant) OR RRID | Not Experimental animals |
| Plants and microbes       | Yes (indicate where provided: section/paragraph) | n/a                           |
| Plants:                   |              | Provide species and strain, unique accession number if available, and source (including location for collected wild specimens) | Not Plants |
| Microbes:                 |              | Provide species and strain, unique accession number if available, and source | Not Microbes |
| Human research participants | Yes (indicate where provided: section/paragraph) | n/a                           |
| Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | The study was approved by the Institutional Review Board of Children’s Hospital of Chongqing Medical University (file no. 2018-02) (the Methods section, the first paragraph) |
| Provide statement confirming informed consent obtained from study participants. | each participant’s statutory guardian signed the informed consent (the Methods section, the first paragraph) |
| Report on age and sex for all study participants. | aged 6–18 and no limit on the gender (the Methods section, the second paragraph) |
### Design

| Study protocol | Yes (indicate where provided): | n/a |
|----------------|-------------------------------|-----|
| For clinical trials, provide the trial registration number OR cite DOI in manuscript. | | Not clinical trials |

| Laboratory protocol | Yes (indicate where provided): | n/a |
|---------------------|-------------------------------|-----|
| Provide DOI or other citation details if detailed step-by-step protocols are available. | | Not Laboratory protocol |

| Experimental study design (statistics details) | Yes (indicate where provided): | n/a |
|------------------------------------------------|-------------------------------|-----|
| State whether and how the following have been done, or if they were not carried out. | | |
| Sample size determination | | No Sample size determination |
| Randomisation | | No Randomisation |
| Blinding | | No Blinding |
| Inclusion/exclusion criteria | V (the Methods section, the second paragraph) | |

| Sample definition and in-laboratory replication | Yes (indicate where provided): | n/a |
|-------------------------------------------------|-------------------------------|-----|
| State number of times the experiment was replicated in laboratory | | Not Sample definition and in-laboratory replication |
| Define whether data describe technical or biological replicates | | Not Sample definition and in-laboratory replication |

| Ethics | Yes (indicate where provided): | n/a |
|--------|-------------------------------|-----|
| Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s)), provide reference number for approval. | The study was approved by the Institutional Review Board of Children’s Hospital of Chongqing Medical University (file no. 2018-02) (the Methods section, the first paragraph) | |
| Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s)), provide reference number for approval. | | No experimental animals |
| Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why. | | No specimen and field samples |

| Dual Use Research of Concern (DURC) | Yes (indicate where provided): | n/a |
|------------------------------------|-------------------------------|-----|
| If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval | | Not Dual Use Research of Concern |
Analysis

| Attribute          | Yes (indicate where provided: section/paragraph) | n/a |
|--------------------|-------------------------------------------------|-----|
| Attrition          | State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance. | the Methods section, the second paragraph |

Statistics

| Description          | Yes (indicate where provided: section/paragraph) | n/a |
|----------------------|-------------------------------------------------|-----|
| Describe statistical tests used and justify choice of tests. | All the data were analyzed by Graphpad Prism 7. Descriptive parameters, including means and standard deviations for normally distributed continuous data, frequencies, and percentages for categorical data, were calculated. Pearson’s x2 test or Fisher’s exact test was used to determine the association between categorical variables. The Mann–Whitney U test was used to compare numerical data between groups, while Spearman’s rank test was used to assess correlations. (the Methods section, the fourth paragraph) |

Data Availability

| Description | Yes (indicate where provided: section/paragraph) | n/a |
|-------------|-------------------------------------------------|-----|
| State whether newly created datasets are available, including protocols for access or restriction on access. | No newly created datasets |
| If data are publicly available, provide accession number in repository or DOI or URL. | No publicly available data |
| If publicly available data are reused, provide accession number in repository or DOI or URL, where possible. | No publicly available data |

Code Availability

| Description | Yes (indicate where provided: section/paragraph) | n/a |
|-------------|-------------------------------------------------|-----|
| For all newly generated code and software essential for replicating the main findings of the study: | No code and software |
| State whether the code or software is available. | No code |
| If code is publicly available, provide accession number in repository, or DOI or URL. | No code |

Reporting

| Adherence to community standards | Yes (indicate where provided: section/paragraph) | n/a |
|---------------------------------|-------------------------------------------------|-----|
| MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR. | ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication. |
| State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript. | ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication. |
Article Information: http://dx.doi.org/10.21037/atm-20-7314